Gefitinib in the treatment of advanced non-small-cell lung cancer

References

• WHO. World Cancer Report. Stewart BW, Kleihues P (Eds). IARC Press, Lyon, France (2003).
   Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest128(4), 2933–2943 (2005).
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ311, 899–909 (1995).
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol.26(28), 4617–4625 (2008).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346(2), 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol.19, 3210–3218 (2001).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol.20, 4285–4291 (2002).
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol.21(16), 3016–3024 (2003).
   PubMed Web of Science ®Google Scholar
• Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol.22(2), 254–261 (2004).
   PubMed Web of Science ®Google Scholar
• Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomized Phase III study of gemcitabine-cisplatin versus etoposide–cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.17(1), 12–18 (1999).
   PubMed Web of Science ®Google Scholar
• Ohe Y, Ohashi Y, Kubota K et al. Randomized Phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann. Oncol.18(2), 317–323 (2007).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von PJ et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(21), 3543–3551 (2008).
   PubMed Web of Science ®Google Scholar
• Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann. Oncol.18(Suppl. 9), ix135–ix142 (2007).
   PubMedGoogle Scholar
• Bunn P Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin. Oncol.29(5 Suppl. 14), 38–44 (2002).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer94(5), 1593–1611 (2002).
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell-lung cancer. Lancet Oncol.4, 397–406 (2003).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res.7(10), 2958–2970 (2001).
   PubMed Web of Science ®Google Scholar
• Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl Cancer Inst.95(12), 851–867 (2003).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol.21, 2787–2799 (2003).
   PubMed Web of Science ®Google Scholar
• Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res.12(24), 7242–7251 (2006).
   PubMed Web of Science ®Google Scholar
• Swaisland H, Laight A, Stafford L et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin. Pharmacokinet.40(4), 297–306 (2001).
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Tamura T, Negoro S et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumours. Ann. Oncol.14(6), 922–930 (2003).
   PubMed Web of Science ®Google Scholar
• Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol.20(9), 2240–2250 (2002).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial. J. Clin. Oncol.20(18), 3815–3825 (2002).
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol.20(21), 4292–4302 (2002).
   PubMed Web of Science ®Google Scholar
• McKillop D, Hutchison M, Partridge EA et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica34(10), 917–934 (2004).
   PubMed Web of Science ®Google Scholar
• McKillop D, Partridge EA, Kemp JV et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol. Cancer Ther.4(4), 641–649 (2005).
   PubMed Web of Science ®Google Scholar
• Haura E, Sommers E, Becker D, McKillop D, Bepler G. Pilot Phase II study of preoperative gefitinib in early stage non-small cell lung cancer with assessment of intratumour gefitinib levels and tumour target modulation. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 7603).
   PubMedGoogle Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol.21(12), 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA290(16), 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs17(4), 401–409 (2006).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366(9496), 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsch V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised Phase III trial (INTEREST). Lancet372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol.26(26), 4244–4252 (2008).
   PubMed Web of Science ®Google Scholar
• Lee D, Kim S, Park K et al. A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 8025).
   Google Scholar
• Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J. Clin. Oncol.22(5), 777–784 (2004).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J. Clin. Oncol.22(5), 785–794 (2004).
   PubMed Web of Science ®Google Scholar
• Crino L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small cell lung cancer (INVITE): a randomised, Phase II study. J. Clin. Oncol.26(26), 4253–4260 (2008).
   PubMed Web of Science ®Google Scholar
• Mok T, Wu Y-L, Thongprasert S et al. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann. Oncol.19(Suppl. 8), viii1 (2008).
   Google Scholar
• Goss G, Ferry D, Wierzbicki R et al. Gefitinib versus placebo in chemonaive patients with advanced non-small cell lung cancer and poor performance status (INSTEP): a randomized Phase II study. J. Clin. Oncol. (2009) (In Press).
   Google Scholar
• Mu X-L, Li L-Y, Zhang X-T, Wang S-L, Wang M-Z. Evaluation of safety and efficacy of gefitinib (‘IRESSA’, ZD1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer4(1), 51–59 (2004).
   PubMed Web of Science ®Google Scholar
• Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA™) monotherapy. Clinical experience in non-small-cell lung cancer. Drug Saf.27(14), 1081–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Kris M, Giaccone G et al. Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2). Lung Cancer41(Suppl. 2), S247 (2003).
   Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn Jr PA et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol.24(31), 5034–5042 (2006).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Androulakis N, Kotsakis A et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter Phase III trial. Lung Cancer59(1), 57–63 (2008).
   PubMed Web of Science ®Google Scholar
• Ramlau R, Gervais R, Krzakowski M et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J. Clin. Oncol.24(18), 2800–2807 (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18(10), 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22(9), 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst.97(9), 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol.23(25), 5892–5899 (2005).
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol.25(12), 1545–1552 (2007).
   PubMed Web of Science ®Google Scholar
• Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer43(3), 317–322 (2004).
   PubMed Web of Science ®Google Scholar
• Kommareddy A, Coplin MA, Gao F et al. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience 1678. Lung Cancer45(2), 221–225 (2004).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Bartolini S, Ceresoli GL et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br. J. Cancer90(1), 82–86 (2004).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Castaldo V, Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br. J. Cancer89, 1827–1829 (2003).
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol.15(7), 1042–1047 (2004).
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Ueoka H et al. Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer46(2), 255–261 (2004).
   PubMed Web of Science ®Google Scholar
• Niho S, Kubota K, Goto K et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol.24(1), 64–69 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Hasegawa Y, Baba K et al. A Phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br. J. Cancer94(11), 1599–1603 (2006).
   PubMed Web of Science ®Google Scholar
• Lin W-C, Chiu C-H, Liou J-L, Chen Y-M, Perng R-P, Tsai C-M. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer54(2), 193–199 (2006).
   PubMedGoogle Scholar
• Lee DH, Han JY, Yu SY et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J. Thorac. Oncol.1(9), 965–971 (2006).
   PubMed Web of Science ®Google Scholar
• Hashizume T, Ogura T, Kozawa S et al. [Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer]. Gan. To Kagaku. Ryoho.33(4), 467–470 (2006).
   PubMedGoogle Scholar
• Yang CH, Yu CJ, Shih JY et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol.26(16), 2745–2753 (2008).
   PubMed Web of Science ®Google Scholar
• Kimura H, Kasahara K, Kawaishi M et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin. Cancer Res.12(13), 3915–3921 (2006).
   PubMed Web of Science ®Google Scholar
• Reck M, Buchholz E, Romer KS, Krutzfeldt K, Gatzemeier U, Manegold C. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. Clin Lung Cancer7(6), 406–411 (2006).
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Burkett ER et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial. Clin. Lung Cancer7(2), 127–132 (2005).
   PubMedGoogle Scholar
• D’Addario G, Rauch D, Stupp R et al. Multicentre Phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann. Oncol.19(4), 739–745 (2008).
   PubMedGoogle Scholar
• Inoue A, Suzuki T, Fukuhara T et al. Prospective Phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol.24(21), 3340–3346 (2006).
   PubMed Web of Science ®Google Scholar
• Sequist LV, Martins R, Spigel DR et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol.26(15), 2442–2449 (2008).
   PubMed Web of Science ®Google Scholar
• Xu JM, Azzariti A, Colucci G, Paradiso A. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother. Pharmacol.52(5), 442–448 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol.26(15), 2450–2456 (2008).
   PubMed Web of Science ®Google Scholar
• Hida T, Okamoto I, Kashii T et al. Randomised Phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG). J. Clin. Oncol.26, (2008) (Abstract LBA8012).
   PubMedGoogle Scholar
• Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal1(1), 12–21 (2000).
   Google Scholar